B+
Bull case
25%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
REVB
Revelation BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The earnings follow-up modestly improves the monitoring setup only if investors accept that the May 7 8-K financial-results update and ongoing AKI study preparation can bridge to a credible 2026 trial-start milestone [#8-K-2026-05-07] [#10-K-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
AKI study-start timing remains uncertain; preparation for a study is not the same as trial initiation or enrollment.
Momentum
86
Value
58
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.40 · Bear $0.45Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $17.75
Why
Momentum86 · Δ7d -
Value58 · Δ7d 0.0
Sentiment46 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • AKI study-start timing remains uncertain; preparation for a study is not the same as trial initiation or enrollment.
- • Additional equity or warrant-linked financing could create further dilution and cap upside even if development milestones improve.
- • The bearish read is that little changed in the core thesis: Revelation still has no revenue, still disclosed substantial doubt about continuing as a going concern in the Q1 10-Q, and still needs additional capital before a clean trial-execution rerating is likely [#10-Q-2026-05-07].
Catalyst clock
2026-08-31
Post-earnings cash update reduced immediate liquidity pressure but did not remove financing risk
Lead driver: Sentiment · See AI snapshot
Momentum
86
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.5
Sentiment
46
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 86.3 / Value 58.0 / Sentiment 46.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.58M
Beta
-0.11
Shares Out
3.98M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.21
Rev YoY
-
EPS YoY
-96.9%
Gross Margin
-
Op Margin
-
Net Debt
-$9.95M
Current Ratio
6.21
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data